Accenture (NYSE: ACN) has invested in Turbine, a predictive simulation startup located in Budapest, Hungary, that is developing a platform for deciphering human biology. Accenture Ventures made the investment.
The deal’s total value was not made public.
Use of funds
The business plans to utilize the money to expand its reach to international biopharma companies so that they may take use of its capacity to unearth biologically concealed insights, which might lead to the acceleration and guidance of important drug development workstreams.
The Simulated CellTM platform, the heart of Turbine technology, uses machine learning to simulate how human cells make choices. The technology meticulously simulates molecular interactions that occur both within and outside of cells, allowing for virtual experiments in volumes that are practically unattainable in the real world and providing insights into the processes behind illness and treatment response.
About Turbine
Turbine, led by CEO Szabolcs Nagy, provides a technology called the Simulated CellTM platform that makes use of machine learning to simulate the decision-making process of human cells.
Pharma firms like AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer are involved in its validation. Turbine has also received money from Accel, MassMutual Ventures, MSD (Merck & Co, Inc. Rahway NJ, USA) Global Health Innovation Fund, and other sources.
